CagriSema vs Wegovy: Stronger Than Semaglutide?

If you have seen headlines calling CagriSema the "next Wegovy" or the drug that finally beats semaglutide, here is the single most important thing to understand before anything else: as of mid-2026, CagriSema is not FDA-approved. You cannot get a prescription for it the way you can for Wegovy. So this comparison is really two separate questions that get tangled together constantly — did CagriSema beat semaglutide in a trial? (a question about evidence) and can you actually get it? (a question about availability). The answers point in different directions, and keeping them apart is the whole point of this article.

The short version: in its pivotal phase 3 trial, CagriSema produced more weight loss than semaglutide alone — a real, meaningful result. But it is a drug that is coming, not one that is here. Wegovy is FDA-approved, on the market, and the thing you can be prescribed today.

What CagriSema actually is

Wegovy is semaglutide — a single molecule, a GLP-1 receptor agonist, made by Novo Nordisk. (If the brand-name maze is confusing, we untangle it in Ozempic vs Wegovy: same drug, different label, and the full mechanism is in our semaglutide evidence guide.)

CagriSema is not one new molecule — it is two drugs given together. It combines cagrilintide, a long-acting analogue of the gut hormone amylin, with semaglutide 2.4 mg, the same GLP-1 drug that is already in Wegovy¹. The logic is to hit two different appetite-regulating pathways at once: GLP-1 (which Wegovy already uses) plus amylin (which it does not). That is why CagriSema is sometimes described as "Wegovy plus a second appetite hormone." The combination was first tested for safety and dosing in a phase 1b trial that co-escalated both drugs over 16 weeks², and the idea was that two complementary mechanisms might out-perform either one alone.

The trial result: CagriSema vs placebo (and the semaglutide question)

The headline evidence is REDEFINE-1, a phase 3a, 68-week, double-blind, placebo- and active-controlled trial published in the New England Journal of Medicine in 2025. It enrolled 3,417 adults with overweight or obesity but without diabetes, randomizing them to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all with lifestyle support¹.

The result for the combination was strong: the estimated mean change in body weight at 68 weeks was -20.4% with CagriSema versus -3.0% with placebo — an estimated difference of about 17.3 percentage points¹. That is a large effect, and it puts CagriSema in the upper tier of weight-loss results reported for this drug class.

Now the part that gets misreported. REDEFINE-1 did include a semaglutide-alone arm, so the "is it stronger than semaglutide?" question was built into the trial design. But the cleanest, most-cited single number from the published trial is CagriSema's roughly 20% weight loss against placebo's roughly 3%¹. For comparison, the benchmark for semaglutide 2.4 mg on its own comes from the STEP 1 trial, where semaglutide produced about -14.9% versus -2.4% on placebo over 68 weeks³. Lining those up — CagriSema ~20% in REDEFINE-1, semaglutide ~15% in STEP 1 — is a fair, honest way to see the gap: the combination does appear to push weight loss meaningfully higher than semaglutide alone. But notice these are two different trials in different populations, so the comparison is indicative, not a clean head-to-head subtraction. (This is the same cross-trial caution we apply in semaglutide vs tirzepatide, where a direct head-to-head trial existed and indirect numbers had to be checked against it.)

One more honest note: early topline press numbers circulated before publication sometimes quoted slightly different figures (for example a ~22.7% headline for CagriSema). The numbers above are from the peer-reviewed published trial using the intention-to-treat (treatment-policy) analysis — those are the figures to trust.

The catch: CagriSema is not approved yet

Here is where the "stronger than semaglutide" excitement has to meet reality. A positive trial is not an approval. As of mid-2026, CagriSema has not been approved by the FDA. Novo Nordisk submitted it to regulators, and a decision is expected later in 2026 — but until that happens, CagriSema is an investigational combination, not a product you can be prescribed. There is no Wegovy-style pen of "CagriSema" at the pharmacy.

That matters enormously for anyone reading this to decide what to do. Wegovy is approved and available now, with a defined label, a known dose ladder, and (for many people) an insurance pathway. CagriSema is a promising result on the horizon. Comparing them as if they were two products on the same shelf is the central mistake — one is on the shelf, the other is in the regulatory queue.

What each has actually proven

Wegovy's evidence is broad and mature. Beyond STEP 1's weight-loss result³, semaglutide at the Wegovy dose has a landmark cardiovascular outcome trial behind it: SELECT showed it reduced major cardiovascular events in adults with obesity and established heart disease but without diabetes⁴. That is a proven outcome benefit, not just a number on a scale, and it is reflected in Wegovy's FDA label⁵. (We cover that heart data in do Wegovy & Ozempic protect the heart? and the real-world experience in Wegovy reviews.)

CagriSema's evidence is newer and narrower — for now. REDEFINE-1 establishes strong weight-loss efficacy versus placebo¹, and a companion trial, REDEFINE-2, tested the combination in adults who do have type 2 diabetes⁶. What CagriSema does not yet have is a published cardiovascular outcome trial of the kind that gives Wegovy its heart-protection claim, and it does not yet have an approval. So "stronger" — if it means "produces more weight loss" — is supported by the weight numbers; but "stronger" in the sense of "more proven, more available, better established" still belongs to Wegovy today.

Side effects: more isn't free

Adding a second active drug does not come without cost. In REDEFINE-1, gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation, abdominal pain — affected about 79.6% of the CagriSema group versus 39.9% on placebo, though they were mostly transient and mild-to-moderate¹. That GI burden is in the same family as semaglutide's own profile (the same nausea-and-gut story we cover for semaglutide side effects), but layering amylin on top of GLP-1 means there is a real tolerability trade-off to watch, not a free upgrade. More appetite suppression tends to mean more gut symptoms.

The bottom line

Did CagriSema beat semaglutide on weight loss? In the trial evidence, broadly yes — REDEFINE-1's roughly 20% weight loss versus placebo sits above semaglutide's roughly 15% benchmark from STEP 1, so the two-hormone combination does appear stronger for the scale¹³. But "stronger in a trial" and "the better choice right now" are not the same sentence. Wegovy is approved, available, and carries a proven cardiovascular benefit; CagriSema is a promising, not-yet-approved combination expected to reach a regulatory decision later in 2026. If you are deciding what to take this year, that is the comparison that actually matters: a real prescription you can start versus a strong result you cannot yet fill. For how the two-drug-pathway logic compares to the other leading approach — tirzepatide's dual GLP-1/GIP mechanism — see semaglutide vs tirzepatide, and to see how semaglutide providers compare on price and oversight today, we rank them in our best semaglutide providers guide.